Nutra Pharma Corp (NPHC)

[cngreen]

2021 the best year ever for our shareholders, our customers, and our patients" stated by the company


1. Nutra Pharma owns over 20 patents and trademarks as well as 119 internet domains.

2. These patents are built around their development of treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenoleukodystrophy(ALS), Adrenomyeloneuropathy(AMN), Rheumatoid Arthritis (RA), Pain, and Myasthenia Gravis (MG).

3. Nutra Pharma is already generating revenue with their Nyloxin®, Pet Pain-Away, and Equine Pain-Away in the over-the-counter pain management market, selling on different platforms such as Amazon, Walmart, and etc. They are selling worldwide in India as well.

4. Already granted Orphan Drug Status on their lead drug RPI-78M for treating Multiple Sclerosis in children.

5. All drugs completed Phase I trial and are ready for next phases II/III.

6. They have been working with private laboratories and governmental agencies to move forward their Nerve Agent Countermeasures and technology. Government grants and contracts are coming as stated in the shareholders letter by company.

7. Research partnership/joint ventures and funding to be announced regarding their lead drug RPI-78M for Multiple Sclerosis, HIV, ALS/AMN

8. In-house manufacturing of drug products including the future productions of RPI-78M. Turning into a cGMP manufacturing facility where the company will be able to make drugs for other drug companies.

9. Laboratory Upgrades, Certifications, and Expansions for the upcoming MS trials and the validation of company's nerve agent counter-measure.

10. Company regaining SEC compliance. Going for PINK and OTCQB status.


Going current, renewing all patents and trademarks. Hired the best SEC lawyers, auditors, and IP attorneys. All toxic notes paid. BIG Things coming!


See below:

Throughout 2021, we expect to continue actively marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away. We are currently working to begin a broad retail rollout that follows our acceptance at Walmart.com. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies.

In 2021, we plan to begin working with joint venture partners to begin clinical trials with our Multiple Sclerosis (MS) drug, RPI-78M under our Orphan designation for pediatric MS. The Orphan status of the drug will allow for faster, less expensive trials as we lay the groundwork for the eventual drug production and trial protocol development. It is our goal to complete the Phase I/II trials in pediatric MS over the next 18-24 months and then either move into Phase III trials or seek a licensing partner.

We also plan to move forward with our work in nerve agent counter-measures and are filing for several grants with US governmental agencies to fund that work.

We believe that we have set the path for a bright future starting with 2021. Sales growth and marketing expansion will allow for a better market for our products and services. Marketing partnerships will bring in strategic investors with a vested interest in the future of our Company.

This will make 2021 our best year ever – for our shareholders, our customers and our patients.


Here is what Deitsch the CEO has done for NPHC in 19 years:

Added Many patents and trademarks to Nutra's portfolio

Clinical Trials in Multiple Phases

1. Multiple Sclerosis Trials

2. Herpes Simplex Infections 1 & 2 Trials

3. Adrenomyeloneuropathy Trials

4. HIV Trials

5. Amyotrophic Lateral Sclerosis Trials

6. Rheumatoid Arthritis Trials

7. Pain Trials

Products launched and brought to Market

1. Cobroxin

2. Nyloxin

3. Pet Pain Away

4. Equine pain Away

Published Research

http://receptopharm.com/drug_development/published_research.php
https://www.nutrapharma.com/research

Increased Sales on Amazon and Walmart

RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis

Huge personal loans from Deitsch to NPHC tells me the CEO knows and believes in NPHC


Why NPHC.

It's the weekend but I was just reading the posts and I decided to basically summarize most of my other posts.

Unfortunately I have more penny stock knowledge than I will ever need thanks to NPHC.

I was attracted to NPHC ten years ago because they actually have patents that could truly make landmark changes to the non-opiod pain market and MS treatment market.

It has been years in the making and I think we all would have preferred it to have played out differently including the NPHC management and the shareholders - but we are here now and what I see is something different.

There is a concerted effort to get current, be transparent, push product development and testing forward to deliver drugs that can make a material impact on patient care. There are so many synergies with JV's, private label options, fully funded MS studies and many penny stocks have paved the road map for NPHC's rise.

I think with all their news and filings in the pipeline and resolution of the SEC case this will easily get bought by big pharma over $0.70 to $1.00. But it doesn't need an acquisition to reach those levels - I think with the massive pain and MS yearly markets we can easily get a reasonable part of that market and even go higher than that.

We have seen it happen countless times this year to stocks with no patents and IP. The market craves these stocks right now. This is the time for NPHC to get current as fast as possible, resolve the SEC case and then drive home it's vast array of patents and products and take advantage of the market and it desire to drive these type of stocks skyward.

After 10 years with this stock I think it finally has found the right time and the market to make it explode any moment.

If indeed they have secured a government grant, in my mind that is affectively a partnership with the US government, forget about it! FORGET ABOUT IT! We will blow past 50 Cent PPS in a few days. ABSOLUTELY PRICELESS! The value of that is UNKNOWN